Roxadustat Versus Daprodustat for Management of Anaemia in Chronic Kidney Disease
Annals of International Medical and Dental Research · 2026-08 · 12 (4) · 43-49
DOI: 10.53339/aimdr.2026.12.4.7 ↗Abstract
Introduction: Anaemia is a frequent complication of chronic kidney disease (CKD) that significantly impacts morbidity, quality of life, and cardiovascular outcomes. Roxadustat and daprodustat, both hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), have emerged as promising oral therapies for its management. The present study aimed to compare the efficacy and safety of roxadustat versus daprodustat in patients with CKD-associated anaemia. Methods: This randomized, open-label, parallel-group clinical trial was conducted in the Department of Nephrology at TMSS Medical College & Rafatullah Community Hospital, Bogura, Bangladesh, between January 2024 and August 2025. A total of 104 adult patients with CKD stages 3–5 and anaemia were enrolled and randomly allocated in a 1:1 ratio to receive either roxadustat (n = 52) or daprodustat (n = 52). Data were analyzed according to the intention-to-treat principle using Statistical Package for the Social Sciences (SPSS) version 26.0. Result: Both groups showed significant improvement in haemoglobin levels over 12 weeks; however, the increase was significantly greater with roxadustat (2.10 ± 1.10 g/dL) than with daprodustat (1.90 ± 1.02 g/dL; P = 0.04). Target haemoglobin levels (10–12 g/dL) were achieved by 78.8% of patients in the roxadustat group and 71.2% in the daprodustat group. Roxadustat also produced a greater reduction in ferritin levels (–50 ± 80 vs –35 ± 75 ng/mL; P = 0.01), while improvements in TSAT were comparable between groups. Conclusion: Roxadustat and daprodustat were both efficient and safe therapies for anaemia in CKD patients, causing a substantial rise in haemoglobin levels and iron metabolism indices. Still, roxadustat showed a slightly but statistically significantly better result in haemoglobin increment and ferritin decrement when compared to daprodustat, while having a safety profile in line with it. Such results imply that these medications are good therapeutic solutions for anaemia in CKD, roxadustat perhaps giving better efficacy in anaemia correction and iron utilization.
EUVIMED